search button

Metastatic breast cancer in patients with schizophrenia

  • Authors:
    • Aaron A. Meyer
    • M. Hwang
    • M. Farasatpour
    • R. Janardhan
    • J. A. Margenthaler
    • K. S. Virgo
    • Frank E. Johnson

  • View Affiliations

  • Published online on: November 27, 2012     https://doi.org/10.3892/mco.2012.44
  • Pages: 359-364
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Breast cancer is a major health problem worldwide. The median survival duration for patients with metastatic breast cancer is two to three years. Approximately 1% of populations worldwide have schizophrenia. The manner in which schizophrenic patients fare when diagnosed with metastatic breast carcinoma (MBC) was evaluated. We queried the National Department of Veterans Affairs (DVA) datasets using computer codes for a pre‑existing diagnosis of schizophrenia and a later diagnosis of breast carcinoma. Chart‑based data concerning the identified subjects were then requested. Previously determined inclusion and exclusion criteria were applied to select evaluable patients from the medical records, prior to extracting demographic details and data concerning the treatment course in each subject. Ten patients had distant metastases at initial diagnosis, while seven developed MBC following prior curative‑intent treatment. Two patients refused therapy. Ten did not comply with recommended management. Five harmed or threatened physicians, other caregivers or themselves. Schizophrenic patients with MBC often fail to understand the nature of their illnesses. Often they do not accept palliative treatment, while a number of them do not comply with therapy, once initiated. They often exhibit behaviors that are detrimental to themselves or others. Formal psychiatric consultation is therefore necessary in patients. Several detrimental behaviors may be predicted reliably by history alone.
View References

Related Articles

Journal Cover

March-April 2013
Volume 1 Issue 2

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.2
  • Ranked
    (total number of cites)
  • CiteScore: 2.6
  • CiteScore Rank: Q3: #242/366 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.693
  • SCImago Journal Rank (SJR): 0.393
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Meyer AA, Hwang M, Farasatpour M, Janardhan R, Margenthaler JA, Virgo KS and Johnson FE: Metastatic breast cancer in patients with schizophrenia. Mol Clin Oncol 1: 359-364, 2013
APA
Meyer, A.A., Hwang, M., Farasatpour, M., Janardhan, R., Margenthaler, J.A., Virgo, K.S., & Johnson, F.E. (2013). Metastatic breast cancer in patients with schizophrenia. Molecular and Clinical Oncology, 1, 359-364. https://doi.org/10.3892/mco.2012.44
MLA
Meyer, A. A., Hwang, M., Farasatpour, M., Janardhan, R., Margenthaler, J. A., Virgo, K. S., Johnson, F. E."Metastatic breast cancer in patients with schizophrenia". Molecular and Clinical Oncology 1.2 (2013): 359-364.
Chicago
Meyer, A. A., Hwang, M., Farasatpour, M., Janardhan, R., Margenthaler, J. A., Virgo, K. S., Johnson, F. E."Metastatic breast cancer in patients with schizophrenia". Molecular and Clinical Oncology 1, no. 2 (2013): 359-364. https://doi.org/10.3892/mco.2012.44